| Year |
Citation |
Score |
| 2020 |
Zhuo Y, Hayashi T, Chen Q, Aggarwal R, Hutin Y, Chhatwal J. Estimating the price at which hepatitis C treatment with direct-acting antivirals would be cost-saving in Japan. Scientific Reports. 10: 4089. PMID 32139872 DOI: 10.1038/S41598-020-60986-4 |
0.383 |
|
| 2019 |
Hatzakis A, Lazarus JV, Cholongitas E, Baptista-Leite R, Boucher C, Busoi CS, Deuffic-Burban S, Chhatwal J, Esmat G, Hutchinson S, Malliori MM, Maticic M, Mozalevskis A, Negro F, Papandreou GA, et al. Securing sustainable funding for viral hepatitis elimination plans. Liver International : Official Journal of the International Association For the Study of the Liver. PMID 31808281 DOI: 10.1111/Liv.14282 |
0.359 |
|
| 2019 |
Dalgic OO, Samur S, Spaulding AC, Llerena S, Cobo C, Ayer T, Roberts MS, Crespo J, Chhatwal J. Improved Health Outcomes from Hepatitis C Treatment Scale-Up in Spain's Prisons: A Cost-Effectiveness Study. Scientific Reports. 9: 16849. PMID 31727921 DOI: 10.1038/S41598-019-52564-0 |
0.371 |
|
| 2019 |
Chen Q, Ayer T, Bethea E, Kanwal F, Wang X, Roberts M, Zhuo Y, Fagiuoli S, Petersen J, Chhatwal J. Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. Bmj Open. 9: e026726. PMID 31189677 DOI: 10.1136/Bmjopen-2018-026726 |
0.376 |
|
| 2019 |
Chhatwal J, Chen Q, Bethea ED, Hur C, Spaulding AC, Kanwal F. The impact of direct-acting anti-virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States. Alimentary Pharmacology & Therapeutics. PMID 31115920 DOI: 10.1111/Apt.15291 |
0.351 |
|
| 2019 |
Ayer T, Zhang C, Bonifonte A, Spaulding AC, Chhatwal J. Prioritizing Hepatitis C Treatment in U.S. Prisons Operations Research. 67: 853-873. DOI: 10.2139/Ssrn.2869158 |
0.341 |
|
| 2019 |
Jahn B, Kurzthaler C, Chhatwal J, Elbasha E, Conrads-Frank A, Rochau U, Sroczynski G, Urach C, Bundo M, Popper N, Siebert U. PCN446 A CASE STUDY OF BREAST CANCER TREATMENT DEMONSTRATING THE IMPACT OF TIME DEPENDENT TRANSITION PROBABILITY ADJUSTMENTS ON COMPARATIVE COST EFFECTIVENESS Value in Health. 22: S522-S523. DOI: 10.1016/J.Jval.2019.09.638 |
0.373 |
|
| 2018 |
Chhatwal J, Sussman NL. Universal Screening for Hepatitis C: An Important Step in Virus Elimination. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 30528843 DOI: 10.1016/J.Cgh.2018.12.002 |
0.311 |
|
| 2018 |
Spaulding AC, Chhatwal J, Adee MG, Lawrence RT, Beckwith CG, Oehsen WV. Funding Hepatitis C Treatment in Correctional Facilities by Using a Nominal Pricing Mechanism. Journal of Correctional Health Care : the Official Journal of the National Commission On Correctional Health Care. 1078345818805770. PMID 30322323 DOI: 10.1177/1078345818805770 |
0.347 |
|
| 2018 |
Bethea ED, Samur S, Kanwal F, Ayer T, Hur C, Roberts MS, Terrault N, Chung RT, Chhatwal J. Cost-effectiveness of Transplanting HCV-Infected Livers into Uninfected Recipients with Preemptive Antiviral Therapy. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 30138735 DOI: 10.1016/J.Cgh.2018.08.042 |
0.354 |
|
| 2018 |
Goel A, Chen Q, Chhatwal J, Aggarwal R. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment. Journal of Gastroenterology and Hepatology. PMID 29864213 DOI: 10.1016/J.Jceh.2018.06.295 |
0.356 |
|
| 2018 |
Chhatwal J, Chen Q, Aggarwal R. Estimation of Hepatitis C Disease Burden and Budget Impact of Treatment Using Health Economic Modeling. Infectious Disease Clinics of North America. 32: 461-480. PMID 29778266 DOI: 10.1016/J.Idc.2018.02.008 |
0.368 |
|
| 2018 |
Spaulding AC, Adee MG, Lawrence RT, Chhatwal J, von Oehsen W. Five Questions Concerning Managing Hepatitis C in the Justice System: Finding Practical Solutions for Hepatitis C Virus Elimination. Infectious Disease Clinics of North America. 32: 323-345. PMID 29778259 DOI: 10.1016/J.Idc.2018.02.014 |
0.384 |
|
| 2018 |
Papatheodoridis GV, Hatzakis A, Cholongitas E, Baptista-Leite R, Baskozos I, Chhatwal J, Colombo M, Cortez-Pinto H, Craxi A, Goldberg D, Gore C, Kautz A, Lazarus JV, Mendão L, Peck-Radosavljevic M, et al. Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe. Journal of Viral Hepatitis. 25: 6-17. PMID 29508946 DOI: 10.1111/Jvh.12875 |
0.351 |
|
| 2018 |
Chhatwal J, Chen Q, Ayer T, Bethea ED, Kanwal F, Kowdley KV, Wang X, Roberts MS, Gordon SC. Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA. Alimentary Pharmacology & Therapeutics. PMID 29377245 DOI: 10.1111/Apt.14527 |
0.355 |
|
| 2018 |
Chen Q, Ayer T, Chhatwal J. Optimal M-Switch Surveillance Policies for Liver Cancer in a Hepatitis C–Infected Population Operations Research. 66: 673-696. DOI: 10.1287/Opre.2017.1706 |
0.327 |
|
| 2018 |
Chhatwal J, Samur S, Li K, Spaulding A, Nwankwo C. Outcomes of delaying hepatitis C treatment in persons who inject drugs: Dynamic modeling of C-EDGE CO-STAR trial cohort Journal of Hepatology. 68: S150-S151. DOI: 10.1016/S0168-8278(18)30513-0 |
0.303 |
|
| 2017 |
Chhatwal J, Samur S, Bethea ED, Ayer T, Kanwal F, Hur C, Roberts MS, Terrault N, Chung RT. Transplanting HCV-positive livers into HCV-negative patients with preemptive antiviral treatment: A modeling study. Hepatology (Baltimore, Md.). PMID 29222916 DOI: 10.1002/Hep.29723 |
0.353 |
|
| 2017 |
Bethea E, Chen Q, Hur C, Chung RT, Chhatwal J. Should we treat acute hepatitis C? A decision and cost-effectiveness analysis. Hepatology (Baltimore, Md.). PMID 29059461 DOI: 10.1002/Hep.29611 |
0.376 |
|
| 2017 |
Chhatwal J. Hepatitis C screening: From modeling to public health policy. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 29020269 DOI: 10.1093/Cid/Cix800 |
0.303 |
|
| 2017 |
Samur S, Bethea ED, Chung RT, Chhatwal J. Cost-effectiveness of pre- vs post-liver transplant hepatitis C treatment: Robustness of results. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 28864272 DOI: 10.1016/J.Cgh.2017.08.030 |
0.331 |
|
| 2017 |
He T, Lopez-Olivo MA, Hur C, Chhatwal J. Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6. Alimentary Pharmacology & Therapeutics. PMID 28836278 DOI: 10.1111/Apt.14271 |
0.383 |
|
| 2017 |
Chhatwal J. Hepatitis C Treatment is Cost-Saving Irrespective of the Perspective. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 28782665 DOI: 10.1016/J.Cgh.2017.07.031 |
0.355 |
|
| 2017 |
Samur S, Kues B, Ayer T, Roberts MS, Kanwal F, Hur C, Donnell DMS, Chung RT, Chhatwal J. Cost-Effectiveness of Pre versus Post Liver Transplant Hepatitis C Treatment with Direct-Acting Antivirals. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 28634131 DOI: 10.1016/J.Cgh.2017.06.024 |
0.381 |
|
| 2017 |
Aggarwal R, Chen Q, Goel A, Seguy N, Pendse R, Ayer T, Chhatwal J. Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India. Plos One. 12: e0176503. PMID 28520728 DOI: 10.1371/Journal.Pone.0176503 |
0.378 |
|
| 2016 |
Kabiri M, Chhatwal J, Donohue JM, Roberts MS, James AE, Dunn MA, Gellad WF. Long-term disease and economic outcomes of prior authorization criteria for Hepatitis C treatment in Pennsylvania Medicaid. Healthcare (Amsterdam, Netherlands). PMID 27932263 DOI: 10.1016/J.Hjdsi.2016.11.001 |
0.385 |
|
| 2016 |
Samur S, Klebanoff M, Banken R, Pratt DS, Chapman R, Ollendorf DA, Loos AM, Corey K, Hur C, Chhatwal J. Long-term Clinical Impact and Cost-Effectiveness of Obeticholic Acid for the Treatment of Primary Biliary Cholangitis. Hepatology (Baltimore, Md.). PMID 27906472 DOI: 10.1002/Hep.28932 |
0.341 |
|
| 2016 |
Chhatwal J, Samur S, Kues B, Ayer T, Roberts MS, Kanwal F, Hur C, Donnell DM, Chung RT. Optimal Timing of Hepatitis C Treatment for Patients on the Liver Transplant Waiting List. Hepatology (Baltimore, Md.). PMID 27906468 DOI: 10.1002/Hep.28926 |
0.379 |
|
| 2016 |
Chen Q, Jain N, Ayer T, Wierda WG, Flowers CR, O'Brien SM, Keating MJ, Kantarjian HM, Chhatwal J. Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016682856. PMID 27870563 DOI: 10.1200/Jco.2016.68.2856 |
0.301 |
|
| 2016 |
Chhatwal J, He T, Hur C, Lopez-Olivo MA. Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection are Cost Saving. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 27650326 DOI: 10.1016/J.Cgh.2016.09.015 |
0.363 |
|
| 2016 |
Chhatwal J, Wang X, Ayer T, Kabiri M, Chung RT, Hur C, Donohue JM, Roberts MS, Kanwal F. Hepatitis C Disease Burden in the United States in the Era of Oral Direct-Acting Antivirals. Hepatology (Baltimore, Md.). PMID 27015107 DOI: 10.1002/Hep.28571 |
0.388 |
|
| 2016 |
Chhatwal J, He T, Lopez-Olivo MA. Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals. Pharmacoeconomics. PMID 26748919 DOI: 10.1007/S40273-015-0373-9 |
0.396 |
|
| 2016 |
Chhatwal J, Li K, He T, Roberts M, Ayer T, Samur S, Grefenstette J, Spaulding A. Hepatitis C Treatment as Prevention: Focusing on United States Prisons Journal of Hepatology. 64: S775. DOI: 10.1016/S0168-8278(16)01511-7 |
0.329 |
|
| 2015 |
He T, Li K, Roberts MS, Spaulding AC, Ayer T, Grefenstette JJ, Chhatwal J. Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons. Annals of Internal Medicine. PMID 26595252 DOI: 10.7326/M15-0617 |
0.357 |
|
| 2015 |
Chhatwal J, Mathisen M, Kantarjian H. Are high drug prices for hematologic malignancies justified? A critical analysis. Cancer. 121: 3372-9. PMID 26102457 DOI: 10.1002/Cncr.29512 |
0.337 |
|
| 2015 |
Chhatwal J, Chen Q, Kanwal F. Why We Should Be Willing to Pay for Hepatitis C Treatment. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 26091736 DOI: 10.1016/J.Cgh.2015.06.005 |
0.34 |
|
| 2015 |
Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Annals of Internal Medicine. 162: 397-406. PMID 25775312 DOI: 10.7326/M14-1336 |
0.394 |
|
| 2015 |
Chhatwal J. Direct-acting antivirals for hepatitis C treatment: Effectiveness versus cost-effectiveness Future Virology. 10: 929-932. DOI: 10.2217/Fvl.15.68 |
0.36 |
|
| 2015 |
Jain N, Chen Q, Ayer T, Wierda WG, O'Brien S, Keating M, Kantarjian HM, Chhatwal J. Prevalence and Economic Burden of Chronic Lymphocytic Leukemia (CLL) in the Era of Oral Targeted Therapies Clinical Lymphoma Myeloma and Leukemia. 15: S30. DOI: 10.1016/J.Clml.2015.07.653 |
0.313 |
|
| 2014 |
Ayvaci MU, Alagoz O, Chhatwal J, Munoz del Rio A, Sickles EA, Nassif H, Kerlikowske K, Burnside ES. Predicting invasive breast cancer versus DCIS in different age groups. Bmc Cancer. 14: 584. PMID 25112586 DOI: 10.1186/1471-2407-14-584 |
0.706 |
|
| 2014 |
Kabiri M, Jazwinski AB, Roberts MS, Schaefer AJ, Chhatwal J. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Annals of Internal Medicine. 161: 170-80. PMID 25089861 DOI: 10.7326/M14-0095 |
0.675 |
|
| 2014 |
He T, Roberts MS, Grefenstette JJ, Chhatwal J. Su1042 Hepatitis C Screening in United States Prisons: Health and Economic Impact on Society Gastroenterology. 146: S-972. DOI: 10.1016/S0016-5085(14)63533-2 |
0.307 |
|
| 2014 |
He T, Roberts M, Grefenstette J, Chhatwal J. Cost-effectiveness of hepatitis C screening in united states prisons: An agent-based approach Value in Health. 17: A37. DOI: 10.1016/J.Jval.2014.03.225 |
0.33 |
|
| 2013 |
Alagoz O, Chhatwal J, Burnside ES. Optimal Policies for Reducing Unnecessary Follow-up Mammography Exams in Breast Cancer Diagnosis. Decision Analysis : a Journal of the Institute For Operations Research and the Management Sciences. 10: 200-224. PMID 24501588 DOI: 10.1287/Deca.2013.0272 |
0.625 |
|
| 2013 |
Chhatwal J, Ferrante SA, Brass C, El Khoury AC, Burroughs M, Bacon B, Esteban-Mur R, Elbasha EH. Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 16: 973-86. PMID 24041347 DOI: 10.1016/J.Jval.2013.07.006 |
0.396 |
|
| 2013 |
Ferrante SA, Chhatwal J, Brass CA, El Khoury AC, Poordad F, Bronowicki JP, Elbasha EH. Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. Bmc Infectious Diseases. 13: 190. PMID 23621902 DOI: 10.1186/1471-2334-13-190 |
0.379 |
|
| 2013 |
Elbasha EH, Chhatwal J, Ferrante SA, El Khoury AC, Laires PA. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal. Applied Health Economics and Health Policy. 11: 65-78. PMID 23355388 DOI: 10.1007/S40258-012-0007-8 |
0.366 |
|
| 2013 |
Ehlers L, Ferrante S, Kristensen M, Leutscher P, Chhatwal J. Cost-Effectiveness of Boceprevir Add-On Treatment of Hepatitis C Virus Genotype 1 Patients in Denmark Value in Health. 16: A354. DOI: 10.1016/J.Jval.2013.08.188 |
0.378 |
|
| 2012 |
Burnside ES, Chhatwal J, Alagoz O. What is the optimal threshold at which to recommend breast biopsy? Plos One. 7: e48820. PMID 23144986 DOI: 10.1371/Journal.Pone.0048820 |
0.609 |
|
| 2012 |
Chhatwal J, Lundberg J, Ferrante S, El Khourhy A, Oksanen A, Elbasha E. 989 COST-EFFECTIVENESS OF BOCEPREVIR IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 1 IN SWEDEN Journal of Hepatology. 56: S386-S387. DOI: 10.1016/S0168-8278(12)61001-0 |
0.364 |
|
| 2012 |
Becker B, Chhatwal J, Ferrante S, Elbasha E, Krobot K. PIN40 Cost-Effectiveness of Boceprevir-Based Treatment of Chronic Genotype 1 Hepatitis C Virus (HCV) Infection From the Perspective of the German Statutory Health Insurance (SHI) Value in Health. 15: A392. DOI: 10.1016/J.Jval.2012.08.1107 |
0.376 |
|
| 2012 |
Odhiambo R, Chhatwal J, Ferrante S, El Khoury A, Elbasha E. PIN32 Economic Evaluation of Boceprevir for the Treatment of Patients With Genotype 1 Chronic Hepatitis C Virus Infection in Hungary Value in Health. 15: A390. DOI: 10.1016/J.Jval.2012.08.1099 |
0.397 |
|
| 2012 |
Becker B, Chhatwal J, Ferrante S, Elbasha E, Krobot K. PIN14 Projecting the Clinical Impact of Treating Hepatitis C Genotype 1 Infection With Boceprevir in Germany Value in Health. 15: A387. DOI: 10.1016/J.Jval.2012.08.1081 |
0.328 |
|
| 2011 |
Ferrante S, Chhatwal J, Dasbach E, El Khoury A, Sniukiene V, Poordad F, Bronowicki J, Brass C. 422 PROJECTING THE CLINICAL IMPACT OF THERAPEUTIC REGIMENS INCLUDING BOCEPREVIR IN PREVIOUSLY UNTREATED ADULT SUBJECTS WITH CHRONIC HEPATITIS C GENOTYPE 1 Journal of Hepatology. 54: S170-S171. DOI: 10.1016/S0168-8278(11)60424-8 |
0.314 |
|
| 2011 |
Chhatwal J, Ferrante S, Dasbach E, El Khoury A, Burroughs M, Bacon B, Esteban-Mur R, Brass C. 409 PROJECTING THE LONG-TERM CLINICAL IMPACT OF BOCEPREVIR IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE-1 WHO FAILED PRIOR TREATMENT WITH PEGINTERFERON/RIBAVIRIN Journal of Hepatology. 54: S164. DOI: 10.1016/S0168-8278(11)60411-X |
0.346 |
|
| 2010 |
Chhatwal J, Alagoz O, Burnside ES. Optimal Breast Biopsy Decision-Making Based on Mammographic Features and Demographic Factors. Operations Research. 58: 1577-1591. PMID 21415931 DOI: 10.1287/Opre.1100.0877 |
0.628 |
|
| 2010 |
Ayer T, Alagoz O, Chhatwal J, Shavlik JW, Kahn CE, Burnside ES. Breast cancer risk estimation with artificial neural networks revisited: discrimination and calibration. Cancer. 116: 3310-21. PMID 20564067 DOI: 10.1002/Cncr.25081 |
0.62 |
|
| 2010 |
Ayer T, Chhatwal J, Alagoz O, Kahn CE, Woods RW, Burnside ES. Informatics in radiology: comparison of logistic regression and artificial neural network models in breast cancer risk estimation. Radiographics : a Review Publication of the Radiological Society of North America, Inc. 30: 13-22. PMID 19901087 DOI: 10.1148/Rg.301095057 |
0.615 |
|
| 2009 |
Burnside ES, Davis J, Chhatwal J, Alagoz O, Lindstrom MJ, Geller BM, Littenberg B, Shaffer KA, Kahn CE, Page CD. Probabilistic computer model developed from clinical data in national mammography database format to classify mammographic findings. Radiology. 251: 663-72. PMID 19366902 DOI: 10.1148/Radiol.2513081346 |
0.575 |
|
| 2009 |
Chhatwal J, Alagoz O, Lindstrom MJ, Kahn CE, Shaffer KA, Burnside ES. A logistic regression model based on the national mammography database format to aid breast cancer diagnosis. Ajr. American Journal of Roentgenology. 192: 1117-27. PMID 19304723 DOI: 10.2214/Ajr.07.3345 |
0.625 |
|
| Show low-probability matches. |